Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6.14M
-
Number of holders
-
14
-
Total 13F shares, excl. options
-
810K
-
Shares change
-
+699K
-
Total reported value, excl. options
-
$4.01M
-
Value change
-
+$3.53M
-
Number of buys
-
12
-
Number of sells
-
-4
-
Price
-
$4.95
Significant Holders of QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) as of Q3 2020
18 filings reported holding QLGN - QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share as of Q3 2020.
QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) has 14 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 810K shares
of 6.14M outstanding shares and own 13.19% of the company stock.
Largest 10 shareholders include BlackRock Inc. (314K shares), VANGUARD GROUP INC (306K shares), GEODE CAPITAL MANAGEMENT, LLC (66.3K shares), CITADEL ADVISORS LLC (53.7K shares), GOLDMAN SACHS GROUP INC (24.8K shares), Cetera Investment Advisers (16.8K shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (15.4K shares), JPMORGAN CHASE & CO (5.6K shares), MORGAN STANLEY (2.94K shares), and Retirement Group, LLC (2K shares).
This table shows the top 14 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.